In relation to combination products, the studies required to meet GMP requirements often include: Response:

Question

Options

• AFinancial impact assessments
• BDrug-device interaction studies
• CConsumer preference surveys
• DLong-term storage tests under various conditions

• A
  3% (1)
• B
  81% (26)
• C
  3% (1)
• D
  13% (4)

Explanation

Drug-device interaction studies (B) are required because combination products - those combining a drug with a medical device, biologic, or another drug - must demonstrate that the drug and device components do not adversely affect each other's safety, efficacy, or performance, which is a core GMP concern for product integrity and patient safety.

Why the distractors are wrong:

• A (Financial impact assessments) - these are business/regulatory strategy tools, not GMP study requirements; GMP focuses on manufacturing quality and safety, not economics.
• C (Consumer preference surveys) - market research belongs to commercial development, not GMP compliance; patient preference has no bearing on whether a product meets manufacturing standards.
• D (Long-term storage tests under various conditions) - while stability testing is a real regulatory requirement, it falls under ICH stability guidelines and is not the defining GMP study for combination products specifically; it also applies broadly to all products, not uniquely to the combination product challenge.

Memory tip: Think "what's unique about combining a drug with a device?" - the core risk is that one component might interfere with the other, so the signature study is the interaction study. If you see "combination product + GMP," link it to Drug-Device Interaction.

No community discussion yet for this question.